50 148
[44]
Schmid M, Rink M, Traumann M, et al. Evidence from the ‘PROspective MulticEnTer RadIcal Cystectomy Series 2011 (PRO- METRICS 2011)’ study: how are preoperative patient characteristics associated with urinary diversion type after radical cystectomy for bladder cancer? Ann Surg Oncol 2015;22:1032–42.
[45]
Fedeli U, Galassi C, Ficarra V, et al. Population-based analyses of radical cystectomy and urinary diversion for bladder cancer in northern Italy. Br J Urol 2010;108:266–71.
[46]
Efstathiou JA, Bae K, Shipley WU, et al. Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol 2009;27:4055–61.[47]
Gray PJ, Fedewa SA, Shipley WU, et al. Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base. Euro Urol 2013;63: 823–9.[48]
Konety BR, Joslyn SA. Factors influencing aggressive therapy for bladder cancer: an analysis of data from the SEER program. J Urol 2003;170:1765–71.[49]
Noon AP, Albertsen PC, Thomas F, Rosario DJ, Catto JW. Competing mortlaity in patients diagnosed with bladder cancer: evidence of udnertreatment in the elderly and female patients. Br J Cancer 2013;108:1534–40.[50]
Cao J, Zhao X, Zhong Z, Zhang L, Zhu X, Xu R. Prognostic value of pre- operative renal insufficiency in urothelial carcinoma: a systematic review and meta-analysis. Sci Rep 2016;6:35214.
[51]
Walter LC, Schonberg MA. Screening mammography in older wom- en: a review. JAMA 2014;311:1336–47.
[52]
Marshall VF, Whitmore WF. The surgical treatment of cancers of the urinary bladder. Cancer 1956;9:609–19.
[53]
Bream M, Maurice M, Altschuler J, Zhu H, Abouassaly R. Increased use of cystectomy in patients 75 or older: a contemporary analysis of survival and perioperative outcomes from the National Cancer database. Urology 2017;100:72–8.[54]
Caillet P, Canoui-Poitrine F, Vouriot J, et al. Comprehensive geriatric assessment in the decision-making process in elderly patients with cancer: ELCAPA study. J Clin Oncol 2011;29:3636–42.
[55]
Decoster L, Van Puyvelde K, Mohile S, et al. Screening tools for multidimensional health problems warranting a geriatric assess- ment in older cancer patients: an update on SIOG recommenda- tions. Ann Oncol 2015;26:288–300.
[56]
Hollenbeck BK, Miller DC, Taub D, et al. Aggressive treatment for bladder cancer is associated with improved overall survival among patients 80 years old or older. Urology 2004;64:292–7.
[57]
Advanced Bladder Cancer Overview Collaboration. Neoadjuvant chemotherapy for invasive bladder cancer. Cochrane database Syst Rev 2005:CD005246.
[58]
Abdollah F, Sun M, Shariat SF, et al. The importance of pelvic lymph node dissection in the elderly population: implications for interpreting the 2010 national comprehensive cancer network practice guidelines for bladder cancer treatment. J Urol 2011;185: 2078–84.
[59]
Reardon ZD, Patel SG, Zaid HB, et al. Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides. Eur Urol 2015;67:165–70.
[60]
Launay-Vacher V, Oudard S, Janus N, et al. Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medica- tions (IRMA) study. Cancer 2007;110:1376–84.
[61]
Chau CSY, Wheater MJ, Geldart TR, Crabb SJ. Comparison of cisplat- in-based neoadjuvant chemotherapy for bladder cancer in elderly versus younger patients. J Clin Oncol 2014;32:15.
[62]
Larcher A, Sun M, Schiffmann J, et al. Differential effect on survival of pelvic lymph node dissection at radical cystectomy for muscle invasive bladder cancer. Eur J Surg Oncol 2015;41:353–60.
[63]
Koppie TM, Vickers AJ, Vora K, Dalbagni G, Bochner BH. Standardi- zation of pelvic lymphadenectomy performed at radical cystec- tomy: can we establish a minimum number of lymph nodes that should be removed? Cancer 2006;107:2368–74.
[64]
May M, Herrmann E, Bolenz C, et al. Association between the number of dissected lymph nodes during pelvic lymphadenectomy and cancer-specific survival in patients with lymph node-negative urothelial carcinoma of the bladder undergoing radical cystectomy. Ann Surg Oncol 2011;18:2018–25.
[65]
Sogni F, Brausi M, Frea B, et al. Morbidity and quality of life in elderly patients receiving ileal conduit of orthotopic neobladder after radical cystectomy for invaisve bladder cancer. Urology 2008;71:919–23.
[66]
Prout GR, WesleyMN, Yancik R, Ries LA, Havlik RJ, Edwards BK. Age and comorbidity impact surgical therapy in older bladder carci- noma patients: a population-based study. Cancer 2005;104: 1638–47.[67]
Froehner M, Brausi MA, Herr HW, Muto G, Studer UE. Complications following radical cystectomy for bladder cancer in the elderly. Eur Urol 2009;56:443–54.
[68]
Schaffar R, Rapiti E, Rachet B, Woods L. Accuracy of cause of death data routinely recorded in a population-based cancer registry: impact on cuase-specific survival and validation using the Geneva Cancer Registry. BMC Cancer 2013;13:609.
[69]
Mieno MN, Tanaka N, Ara T, et al. Accuracy of death certificates ans assessment of factors for misclassification of underlying cause of death. J Epidemiol 2016;26:191–8.
[70]
Bellmunt J, Orsola A, Maldonado X, Kataja V, Group EGW. Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 5):134–6.[71]
Kouloulias V, Mosa E, Tolia M, et al. Evaluation of efficacy and toxicity in two different hypofractionated 3D-conformal external beam radiotherapy schedules in localised muscle invasive bladder cancer. J BUON 2013;18:942–8.
E U R O P E A N U R O L O G Y 7 3 ( 2 0 1 8 ) 4 0 – 5 0
50